Gong, Xian; Du, Jianting; Peng, Ren-Wang; Chen, Chun; Yang, Zhang (2024). CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research. Cancers, 16(2) MDPI AG 10.3390/cancers16020460
|
Text
cancers-16-00460-v2.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Once considered "undruggable" due to the strong affinity of RAS proteins for GTP and the structural lack of a hydrophobic "pocket" for drug binding, the development of proprietary therapies for KRAS-mutant tumors has long been a challenging area of research. CRISPR technology, the most successful gene-editing tool to date, is increasingly being utilized in cancer research. Here, we provide a comprehensive review of the application of the CRISPR system in basic and translational research in KRAS-mutant cancer, summarizing recent advances in the mechanistic understanding of KRAS biology and the underlying principles of drug resistance, anti-tumor immunity, epigenetic regulatory networks, and synthetic lethality co-opted by mutant KRAS.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Thoraxchirurgie 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery |
UniBE Contributor: |
Peng, Ren-Wang |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2072-6694 |
Publisher: |
MDPI AG |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
29 Jan 2024 10:25 |
Last Modified: |
29 Jan 2024 10:34 |
Publisher DOI: |
10.3390/cancers16020460 |
PubMed ID: |
38275900 |
Uncontrolled Keywords: |
CRISPR KRAS gene editing resistance synthetic lethal |
BORIS DOI: |
10.48350/192186 |
URI: |
https://boris.unibe.ch/id/eprint/192186 |
Actions (login required)
 |
Edit item |